New Delhi, February 12 Natco Pharma announced on Thursday that its consolidated net profit increased by 14% year-on-year to Rs 151 crore for the third quarter ended December 31, 2025.
The drug firm reported a net profit of Rs 132 crore for the October-December quarter of the previous fiscal year.
Revenue from operations rose to Rs 647 crore for the period under review, compared with Rs 475 crore in the year-ago period, Natco Pharma said in a regulatory filing.
The company's board has declared a third interim dividend of Rs 1.5 per share for the financial year 2025-26.
The board also approved the re-appointment of Venkaiah Chowdary Nannapaneni as Chairman and Managing Director for a period of one year, effective from April 1, 2026.
The board also approved the incorporation of a wholly-owned subsidiary in Chile with an investment of up to USD 3 lakh.
Shares of Natco Pharma ended 1.28% down at Rs 839.90 apiece on the BSE on Thursday.